AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings ...
Nearly half a million Americans visit the emergency room (ER) each year with a fast-spreading stomach bug called norovirus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback